Evidence map›Paper›PMID 40723827›Full record

ArticleBiomolecules2025

Presenilin-1 Familial Alzheimer Mutations Impair γ-Secretase Cleavage of APP Through Stabilized Enzyme-Substrate Complex Formation.

Sujan Devkota, Masato Maesako, Michael S Wolfe

Abstract read
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sujan DevkotaDepartment of Medicinal Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Masato MaesakoMass General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02131, USA.ORCID 0000-0002-1970-2462
Michael S WolfeDepartment of Medicinal Chemistry, University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-5721-9092

Funding

Structure and Function of Gamma-Secretase in Familial Alzheimer's DiseaseR01AG066986 · NIA · UNIVERSITY OF KANSAS LAWRENCE · PI Yinglong Miao, Michael S Wolfe · 2020 to 2026
$3.6M
Leveraging Heterogeneity in Autosomal Dominant AD to Elucidate Pathophysiology and Improve AD BiomarkersR01AG079569 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI JASMEER P CHHATWAL, Michael S Wolfe · 2025 to 2026
$2.8M
NIA NIH HHS R01 AG066986NIA NIH HHS R01 AG079569NIH HHS 1R01AG066986-05NIH HHS 1RF1AG079569-03
6 · The paper itself

Abstract

Familial Alzheimer's disease (FAD) is caused by dominant missense mutations in amyloid precursor protein (APP) and presenilin-1 (PSEN1), the catalytic component of γ-secretase that generates amyloid β-peptides (Aβ) from the APP C-terminal fragment C99. While most FAD mutations increase the ratio of aggregation-prone Aβ42 relative to Aβ40, consistent with the amyloid hypothesis of Alzheimer pathogenesis, some mutations do not increase this ratio. The γ-secretase complex produces amyloid β-peptide (Aβ) through processive cleavage along two pathways: C99 → Aβ49 → Aβ46 → Aβ43 → Aβ40 and C99 → Aβ48 → Aβ45 → Aβ42 → Aβ38. Understanding how FAD mutations affect the multistep γ-secretase cleavage process is critical for elucidating disease pathogenesis. In a recent study, we discovered that FAD mutations lead to stalled γ-secretase/substrate complexes that trigger synaptic loss independently of Aβ production. Here, we further investigate this "stalled complex" hypothesis, focusing on five additional PSEN1 FAD mutations (M84V, C92S, Y115H, T116I, and M139V). A comprehensive biochemical analysis revealed that all five mutations led to substantially reduced initial proteolysis of C99 to Aβ49 or Aβ48 as well as deficiencies in one or more subsequent trimming steps. Results from fluorescence lifetime imaging microscopy support increased stabilization of enzyme-substrate complexes by all five FAD mutations. These findings provide further support for the stalled complex hypothesis, highlighting that FAD mutations impair γ-secretase function by promoting the accumulation of stalled enzyme-substrate complexes.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesMutationPresenilin-1Amyloid beta-PeptidesHumansProteolysisAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesPresenilin-1PSEN1 protein, humanamyloid β-peptidefluorescence microscopymass spectrometryprotease

Identifiers

PMID40723827
PMCPMC12292344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.